Report suggests steps to improve safety of drug supply

Traynor, Kate
September 2011
American Journal of Health-System Pharmacy;9/1/2011, Vol. 68 Issue 17, p1570
Academic Journal
The article discusses the report "After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs," by Pew Charitable Trusts' Health Group. The issues raised by the report include the need for a track-and-trace system, uniform standards for unit-of-use-level drug product serialization, and compliance with good manufacturing practices. Included are comments from Deborah Autor, former director of the Office of Compliance in FDA's Center for Drug Evaluation and Research.


Related Articles

  • More transparency hasn't translated into import safety. SEREBROV, MARI // Medical Device Daily;5/28/2013, Vol. 17 Issue 102, p1 

    The article talks about the continued concern for safety by the U.S. regarding Chinese imports despite increase in transparency and collaboration between the two nations. The author says that the U.S. Food and Drug Administration (FDA) has 74 active import alerts with regards to drugs and...

  • FDA calls for risk-rating health IT. Lee, Jaimy // Modern Healthcare;4/7/2014, Vol. 44 Issue 14, p13 

    The article reports that the U.S. Food and Drug Administration has proposed that the health information technology products should be classified on the basis of their potential risks to patient safety, as of April 2014 and presents views of Jeffrey Shuren of FDA on the proposal, as of April 2014.

  • Are drugs made abroad safe to take?  // Consumer Reports on Health;Sep2014, Vol. 26 Issue 9, p9 

    The article discusses safety issues that have been found to be associated with medications that are sold in the U.S. and are manufactured in foreign countries, including India and China. Warning letters related to drug manufacturing which the U.S. Food and Drug Administration sent to drug...

  • App lets users submit device reports to FDA.  // Dermatology Times;Jul2013, Vol. 34 Issue 7, p21 

    The article offers information on the MedWatcher mobile application, which allows users to submit reports of serious medical device problems to the U.S. Food and Drug Administration.

  • Keeping big pharma in check? Kassirer, Jerome P. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/12/2011, Vol. 342 Issue 7797, p602 

    The article reviews the book "Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA," by Daniel Carpenter.

  • FDA Issues Draft Guidance on Crude Heparin Quality. Ritter, Amy // BioPharm International;Mar2012, Vol. 25 Issue 3, p10 

    The article reports that the U.S. Food and Drug Administration (FDA) releases a draft guidance for active pharmaceutical ingredients (API) manufacturers, pharmaceutical and medical-device manufacturers, and others to the possible risk of crude heparin contamination.

  • Good Manufacturing Practice: A Pharmacist's Perspective. Stricker, Steve // Oncology Nurse-APN/PA;Sep/Oct2014 Supplement Conquering The Cancer Care Cotinuum, p5 

    No abstract available.

  • Bad medicine. Grens, Kerry // Modern Healthcare;5/20/2013, Vol. 43 Issue 20, p30 

    The article discusses the global efforts to stop the use of poor-quality drugs. The World Health Organization (WHO) revealed that 30% of United Nations (UN) members do not have adequate regulatory oversight of drugs. Non-profit organization U.S. Pharmacopoeia (USP) has launched a program to...

  • Risky-drugs list in the spotlight. Rhea, Shawn // Modern Healthcare;8/9/2010, Vol. 40 Issue 32, p14 

    The article reports that healthcare professionals, patient groups and drug manufacturers are concerned about the list of drug-safety requirements issued under the U.S. Food and Drug Administration's Risk Evaluation and Mitigation Strategies (REMS). They agree that the program is needed to allow...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics